Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias

Zhihong Zeng(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington), Ismael Samudio(BC Cancer Agency), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Ziwei Huang(Nanjing University of Chinese Medicine), Jing An(SUNY Upstate Medical University), Mark F. Munsell(The University of Texas MD Anderson Cancer Center)
Molecular Cancer Therapeutics
December 1, 2006
10.1158/1535-7163.mct-06-0228
Cited by 186

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k